Achillion Pharmaceuticals is currently carrying out phase 2 clinical trials of their drug ACH-0144471, a Factor D inhibitor with the aim of treating C3G.
For more details including inclusion and exclusion criteria for the trial please follow this link to clinicaltrials.gov https://clinicaltrials.gov/show/NCT03369236
As you will see there are multiple locations/centres for the trial throughout the world including one in the UK. If you are interested in taking part in the trial and are UK based please get your nephrologist to contact Professor Liz Lightstone PhD FRCP at Imperial College London via e-mail at l.lightstone@imperial.ac.uk
Non UK patients can find trial location information on clinicaltrials.gov. Achillion can be contacted on 2037525566 or C3GTrialInquiries@achillion.com